Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial

被引：0
|
作者：
Le Heuzey, Jean-Yves [1 ]
Marijon, Eloi [1 ]
Connolly, Stuart [2 ]
Brueckmann, Martina [3 ]
Yang, Sean [2 ]
Pogue, Janice [2 ]
Eikelboom, John [2 ]
Ezekowitz, Michael [4 ]
Themeles, Ellison [2 ]
Wallentin, Lars [5 ]
Yusuf, Salim [2 ]
机构：
[1] Hop Europeen Georges Pompidou, Paris, France
[2] Populat Hlth Rsch Inst, Hamilton, ON, Canada
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Cardiovasc Rsch Fdn, Wynnewood, PA USA
[5] Uppsala Clin Rsch Cntr, Uppsala, Sweden
来源：
STROKE | 2013年 / 44卷 / 02期
关键词：
Sudden cardiac death; Heart failure; Embolism; Anticoagulation; Atrial fibrillation;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
    Paikin, Jeremy S.
    Haroun, Michelle J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 279 - 286
  • [2] Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
    Marin, Francisco
    Roldan, Vanessa
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1087 - 1090
  • [3] Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
    DiNicolantonio, James J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1101 - 1111
  • [4] Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial
    Diener, H. C.
    Marijon, E.
    Le Heuzey, J. -Y.
    Connolly, S.
    Noack, H.
    Brueckmann, M.
    Eikelboom, J.
    Ezekowitz, M.
    Clemens, A.
    Reilly, P.
    Wallentin, L.
    Yusuf, S.
    CEREBROVASCULAR DISEASES, 2013, 35 : 165 - 165
  • [5] Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial
    Ezekowitz, M. D.
    Connolly, S. J.
    Fraessdorf, M.
    Brueckmann, M.
    Kreuzer, J.
    Oldgren, J.
    Reilly, P.
    Yusuf, S.
    Wallentin, L.
    EUROPEAN HEART JOURNAL, 2015, 36 : 862 - 862
  • [6] CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY® TRIAL
    Nagarakanti, Rangadham
    Connolly, Stuart
    Fraessdorf, Mandy
    Brueckmann, Martina
    Kreuzer, Joerg
    Reilly, Paul
    Oldgren, Jonas
    Yusuf, Salim
    Wallentin, Lars
    Ezekowitz, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 802 - 802
  • [7] Stroke prevention in atrial fibrillation: late-breaking insights from the RE-LY trial
    Wijnmaalen, A. P.
    NETHERLANDS HEART JOURNAL, 2009, 17 : 20 - 21
  • [8] Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
    Boehm, Michael
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Eikelboom, John W.
    Hohnloser, Stefan H.
    Reilly, Paul A.
    Schumacher, Helmut
    Brueckmann, Martina
    Schirmer, Stephan H.
    Kratz, Mario T.
    Yusuf, Salim
    Diener, Hans-Christoph
    Hijazi, Ziad
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (23) : 2481 - 2493
  • [9] Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
    Khoo, Chee W.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) : 685 - 687
  • [10] Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: the RE-LY study
    Diener, H. C.
    Connolly, S. J.
    Ezekowitz, M.
    Yusuf, S.
    Wallentin, L.
    Reilly, P.
    Pogue, J.
    Wang, S.
    Xavier, D.
    Di Pasquale, G.
    JOURNAL OF NEUROLOGY, 2010, 257 : S31 - S31
12345